Related Experiment Video
Updated: May 12, 2026
09:57
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Management options for refractory chronic myeloid leukemia: considerations for the elderly
Massimo Breccia1, Giuliana Alimena
1Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy. breccia@bce.uniroma1.it
Drugs & Aging
|April 26, 2013
Summary
Second-generation tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib offer effective alternatives for chronic myeloid leukemia patients resistant to imatinib. These TKIs demonstrate similar efficacy in older adults, improving treatment outcomes.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Standard-dose imatinib is effective for chronic myeloid leukemia (CML) in the chronic phase, but resistance develops in one-third of patients.
- Drug resistance necessitates alternative therapies, leading to the development of second-generation tyrosine kinase inhibitors (TKIs).
Purpose of the Study:
- To review mechanisms of imatinib resistance in CML.
- To discuss management options for refractory CML patients, with a focus on older adults.
- To evaluate the efficacy of second-generation TKIs (dasatinib and nilotinib) in imatinib-resistant CML.
Main Methods:
- Review of in vitro and in vivo studies on CML resistance mechanisms.
- Analysis of clinical trial data for second-generation TKIs in imatinib-resistant and -intolerant CML patients.
- Comparative efficacy assessment of dasatinib and nilotinib in older CML patients.
Main Results:
- Second-generation TKIs (dasatinib, nilotinib) are effective in patients resistant to imatinib.
- These TKIs show efficacy in older CML patients.
- First-line use of second-generation TKIs improves cytogenetic and molecular response rates and reduces disease progression.
- No significant efficacy differences were observed between nilotinib and dasatinib in imatinib-resistant older patients.
- First-line second-generation TKI treatment yields similar results in older and younger patients.
Conclusions:
- Second-generation TKIs represent a crucial advancement for managing imatinib-resistant CML.
- Dasatinib and nilotinib offer effective treatment options, including for older patients, both in first-line and subsequent settings.
- Further research may refine optimal sequencing and combination strategies for CML treatment.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Chronic Kidney Disease IV: Nursing Management
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...